🛰️ Daily AI Frontier
‹ back to 2026-09-12

PLA2G2D in tumour-draining lymph nodes regulates anti-tumour immunity

Nature Medical/Healthcare AI Anneloes van Krimpen, Julie Huang, Mike Eterman, Vivian Gerretsen, Michihisa Umetani, Josephine C. Janssen, Menno van Nimwegen, Nina Rozendaal, Thierry P. P. van den Bosch, Xinguo Jiang, Kathryn Logronio, Angela Z. Liu, Yun-Ru Liu, Yuki Nagasaki, Makoto Murakami, Anne Onrust-Van Schoonhoven, Asabi Leliveld, Disha Vadgama, Hedwig Langeveld, Rogier van Wijck, Eric Bindels, Jan von der ThĂĽsen, Antien Mooyaart, Febe van Maldegem, Claudia M. Brenis, Stijn Verwaerde, Rudi W. Hendriks, Bart N. Lambrecht, Dirk J. GrĂĽnhagen, Cornelis Verhoef, Joachim G. J. V. Aerts, Li-Fen Lee, Kan V. Lu, Ralph Stadhouders, Floris Dammeijer 2026-09-09

TL;DR - A Nature study identifies PLA2G2D-high macrophages in tumour-draining lymph nodes as regulators of anti-tumour immunity and links them to poor patient prognosis. Inhibiting PLA2G2D improved immune responses against tumours in mouse models, suggesting a potential therapeutic target.

  • The implicated macrophage population expresses high levels of the enzyme PLA2G2D.
  • These cells reside in tumour-draining lymph nodes and are associated with poor prognosis in patients.
  • PLA2G2D inhibition enhanced anti-tumour immunity in mouse models.
  • The provided summary does not report the inhibitor, cancer types, or clinical efficacy.

view merged work →